Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oscillatory Contributions to Working Memory and Attention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03787134
Recruitment Status : Recruiting
First Posted : December 25, 2018
Last Update Posted : April 24, 2019
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:

The objectives are articulated in the proposal's specific aims:

Aim 1: To test the hypothesis that the cognitive control of unattended memory items (UMI) is implemented by the same frontoparietal mechanisms that control spatial and nonspatial attention.

Aim 2: To test the hypothesis that the selection of visual stimuli, whether from the environment or from WM, is accomplished, in part, by the hijacking of low-frequency oscillatory dynamics that are fundamental to the waking-state physiology of the corticothalamic circuitry of the visual system.

Aim 3: To test the hypothesis that the function of context binding contributes to delay-period activity of the posterior parietal cortex (PPC).


Condition or disease Intervention/treatment Phase
Young Adults Behavioral: working memory and attention Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 269 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Oscillatory Contributions to Working Memory and Attention
Actual Study Start Date : March 1, 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory

Arm Intervention/treatment
Experimental: 2016-0500-Healthy YoungAdults
working memory and attention
Behavioral: working memory and attention
Behavioral tests of working memory and attention




Primary Outcome Measures :
  1. Experiment 1.a. Behavioral accuracy [ Time Frame: 3 hours ]
    Mean percentage of responses that are correct

  2. Experiment 1.a. Reaction time [ Time Frame: 3 hours ]
    The time, measured in milliseconds, that it takes a subject to press the "match" or "nonmatch" button after the memory probe appears.

  3. Experiment 1.a. Changes in multivariate pattern classification of electroencephalography data in response to prioritization cues and in response to pulses of transcranial magnetic stimulation. [ Time Frame: 3 hours ]
    Multivariate pattern classification is a method from machine learning that can be used to assess the neural representation of stimulus information in electroencephalographic signal (i.e., to "decode" the signal). The outcome measure is how decoder performance will change as a function of a stimulus's priority status, and in response to a pulse of transcranial magnetic stimulation. Note that this method entails analysis of the broadband electroencephalographic signal (bandpass filtered from 1-100Hz) in each of two formats: time domain, and spectrally transformed. The spectrally transformed analysis does not entail the separate analysis of discrete functionally defined frequency bands (e.g., alpha, beta, etc.) Rather, spectral power values at every integer frequency from 2 to 20 Hz and every other integer from 22 to 50 Hz - yielding 34 frequencies per channel - are used as features in the analysis.

  4. Experiment 1.a. Spatially distributed phase coupling extraction-identified components of the transcranial magnetic stimulation-evoked electroencephalography signal [ Time Frame: 3 hours ]
    Spatially distributed phase coupling extraction-identified components of the transcranial magnetic stimulation-evoked electroencephalography signal will indicate whether the unattended memory item reactivation effect is carried by a de novo component in the electroencephalography signal or by a change in the power of one or more beta components that were present in the signal prior to the delivery of transcranial magnetic stimulation. Note that this method entails analysis of a spectral transformation of the broadband electroencephalographic signal that does not entail the separate analysis of discrete functionally defined frequency bands (e.g., alpha, beta, etc.) Rather, spectral power values at every integer frequency from 2 to 20 Hz and every other integer from frequency from 22 to 30 Hz - yielding 24 frequencies per channel - are entered into the analysis. No a priori assumptions are made about the frequency composition of components that the method will identify.

  5. Experiment 2.a. The amplitude of multivariate inverted encoding model-reconstructions of stimulus location, derived from the transcranial magnetic stimulation-evoked response [ Time Frame: 5 hours ]
    Multivariate inverted encoding modeling will be used to reconstruct the representation of stimulus locations from the electroencephalography data, and the strength of the representation will be compared across three stimulus conditions. Note that this method entails analysis of the broadband electroencephalographic signal (bandpass filtered from 1-100Hz) in each of two formats: time domain, and spectrally transformed. The spectrally transformed analysis does not entail the separate analysis of discrete functionally defined frequency bands (e.g., alpha, beta, etc.). Rather, spectral power values at every integer frequency from 2 to 20 Hz and at every other integer frequency from 22 to 50 Hz - yielding 34 frequencies per channel -- are used as features in the analysis.

  6. Experiment 2.a. Spatially distributed phase coupling extraction-identified components of the transcranial magnetic stimulation-evoked electroencephalography signal [ Time Frame: 5 hours ]
    Spatially distributed phase coupling extraction-identified components of the transcranial magnetic stimulation-evoked electroencephalography signal will indicate whether the unattended memory item reactivation effect is carried by a de novo component in the electroencephalographic signal, or by a change in the power of one or more components that were present in the signal prior to the delivery of transcranial magnetic stimulation. Note that this method entails analysis of a spectral transformation of the broadband electroencephalographic signal that does not entail the separate analysis of discrete functionally defined frequency bands (e.g., alpha, beta, etc.) Rather, spectral power values at every integer frequency from 2 to 20 Hz and every other integer from frequency from 22 to 30 Hz - yielding 24 frequencies per channel - are entered into the analysis. No a priori assumptions are made about the frequency composition of components that the method will identify.

  7. Experiment 2.a. Correlation of the amplitude of multivariate inverted encoding model-reconstructions of the location of the unattended memory item with alpha band power. [ Time Frame: 5 hours ]
    Correlation of the amplitude of multivariate inverted encoding model-reconstructions of the location of the unattended memory item, derived from the transcranial magnetic stimulation-evoked response, with alpha band power when targeting occipital cortex.

  8. Experiment 2.a. Correlation of the amplitude of multivariate inverted encoding model-reconstructions of the location of the unattended memory item with beta-band power [ Time Frame: 5 hours ]
    Correlation of the amplitude of multivariate inverted encoding model-reconstructions of the location of the unattended memory item, derived from the transcranial magnetic stimulation-evoked response, with beta-band power when targeting the intraparietal sulcus.

  9. Experiment 3.a. Power in the alpha band of the EEG as a function of retinotopic location [ Time Frame: 4 hours ]
    Power in the alpha band of the EEG as a function of retinotopic location

  10. Experiment 3.a. Frequency in the alpha band of the EEG as a function of retinotopic location [ Time Frame: 4 hours ]
    Frequency in the alpha band of the EEG as a function of retinotopic location

  11. Experiment 3.a. Spatially distributed phase coupling extraction-identified components of the electroencephalography signal from signals corresponding to the attended location [ Time Frame: 4 hours ]
    Spatially distributed phase coupling extraction-identified components of the electroencephalography signal from signals corresponding to the attended location to assess whether expectation-related shifts in alpha-band frequency are produced by a change in the frequency of one oscillator or by a change in the relative power of multiple oscillators.

  12. Experiment 4.a. Behavioral accuracy assessed as mean percentage correct responses. [ Time Frame: 4 hours ]
    Behavioral accuracy assessed as mean percentage correct responses.

  13. Experiment 4.a. Reaction time assess as latency to press response button after onset of critical stimulus. [ Time Frame: 4 hours ]
    Reaction time assess as latency to press response button after onset of critical stimulus.

  14. Experiment 4.a. Power in the alpha band of the EEG as a function of retinotopic location [ Time Frame: 4 hours ]
    Power in the alpha band of the EEG as a function of retinotopic location

  15. Experiment 4.a. Frequency in the alpha band of the EEG as a function of retinotopic location [ Time Frame: 4 hours ]
    Frequency in the alpha band of the EEG as a function of retinotopic location

  16. Experiment 4.a. Spatially distributed phase coupling extraction-identified alpha-band components of the electroencephalography signal from signals corresponding to the attended location [ Time Frame: 4 hours ]
    Spatially distributed phase coupling extraction-identified components of the electroencephalography signal from signals corresponding to the attended location to assess whether expectation-related shifts in alpha-band frequency are produced by a change in the frequency of one oscillator or by a change in the relative power of multiple oscillators.

  17. Experiment 5. The amplitude of the "contralateral delay activity" (CDA) slow component of the EEG during the time period from 1000-1600 milliseconds after stimulus array onset. [ Time Frame: 4 hours ]
    The amplitude of the CDA slow component of the EEG during the time period from 1000-1600 milliseconds after stimulus array onset. Note that this is an event-related potential analysis in which time-domain datas are trial averaged. The data are not spectrally transformed, so functionally defined frequency bands in the EEG (e.g., alpha, beta, etc.) are not relevant for this outcome.

  18. Experiment 5. Multivariate inverted encoding modeling of the EEG signal to determine whether or not stimulus information is carried in this signal. [ Time Frame: 4 hours ]
    Multivariate inverted encoding modeling of the EEG signal to determine whether or not stimulus information is carried in this signal. Note that this method entails analysis of the broadband electroencephalographic signal (bandpass filtered from 1-100Hz) in each of two formats: time domain, and spectrally transformed. The spectrally transformed analysis does not entail the separate analysis of discrete functionally defined frequency bands (e.g., alpha, beta, etc.). Rather, spectral power values at every integer frequency from 2 to 20 Hz and at every other integer frequency from 22 to 50 Hz - yielding 34 frequencies per channel -- are used as features in the analysis.

  19. Experiment 6. Multivariate inverted encoding modeling of the EEG signal to determine whether or not contextual information is carried in this signal [ Time Frame: 4 hours ]
    Multivariate inverted encoding modeling of the EEG signal to determine whether or not contextual information is carried in this signal. Note that this method entails analysis of the broadband electroencephalographic signal (bandpass filtered from 1-100Hz) in each of two formats: time domain, and spectrally transformed. The spectrally transformed analysis does not entail the separate analysis of discrete functionally defined frequency bands (e.g., alpha, beta, etc.). Rather, spectral power values at every integer frequency from 2 to 20 Hz and at every other integer frequency from 22 to 50 Hz - yielding 34 frequencies per channel -- are used as features in the analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age of # 18 <36. - Right-handed.
  • Be in good health determined by the investigator on basis of medical history, physical and neurological exam; for "EEG-only" sessions no physical or neurological exams will be performed;
  • Female subjects must be two years past menopause, surgically sterile or practicing a medically acceptable method of birth control (does not apply to "EEG-only" sessions);
  • Female subjects must not be pregnant.
  • Able to understand and speak English.
  • Able to provide written consent prior to admission

Exclusion Criteria:

  • History of epilepsy, stroke, brain surgery, cranial metal implants, structural brain lesion, devices that may be affected by TMS or tCS(pacemaker, medication pump, cochlear implant, implanted brain stimulator); - Women who are breast-feeding (self report)*;
  • History of head trauma with loss of consciousness for greater than 5 minutes;
  • Any history of seizures;
  • Any family history of seizures*;
  • Diabetes requiring insulin treatment*;
  • A serious heart disorder or subjects who have had a heart attack within the last 3 months;
  • Subjects who meet DSM-IV criteria for alcohol /drug abuse problems within the last six months;
  • Any current Axis I or II diagnoses or past Axis I diagnoses;
  • Required use of medication that affects CNS function;
  • A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MR machine can cause a displacement or malfunctioning of these devices*;
  • The female subject who is pregnant or planning to become pregnant; or a female subject of child-bearing potential who is not practicing a medically acceptable form of birth control*;
  • The subject has had a diagnosis of cancer in the past 3 years and/or has active neoplastic disease;
  • The investigator anticipates that the subject will be unable to comply with the protocol.
  • Prohibited Concomitant Treatment: Any investigational medication; antipsychotic, antidepressant; or ECT; Other psychotropic medications including sedative hypnotics (excluding chloral hydrate zaleplon); sumatriptan (and similar agents); anxiolytics and herbals (e.g., St. John's Wort, Kava Kava); an introduction or change in intensity of psychotherapy; any nonpsychopharmacologic drug with psychotropic effects (e.g., antihistamines, beta blockers).
  • Colorblindness
  • Poor or Uncorrected Vision
  • History of fainting/syncope

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787134


Contacts
Layout table for location contacts
Contact: Jacqueline Fulvio, PhD 6082658961 Jacqueline.Fulvio@wisc.edu
Contact: Bradley R Postle, PhD 6083450980 postle@wisc.edu

Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin - Madison Recruiting
Madison, Wisconsin, United States, 53706
Contact: Susan Stautz    608-263-9119    sstautz@wisc.edu   
Sponsors and Collaborators
University of Wisconsin, Madison

Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT03787134     History of Changes
Other Study ID Numbers: 2016-0500
First Posted: December 25, 2018    Key Record Dates
Last Update Posted: April 24, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No